Overseas MDMA and psilocybin makers eye U.S. market as regulatory landscape eases

Companies that produce MDMA and psilocybin for patients abroad are turning their attention to the United States, hoping to leverage experience gained under more permissive foreign rules. Rising policy support, unmet mental‑health needs and interest from large pharma firms are driving this shift.

The path is not without hurdles, as U.S. regulators impose additional controls on scheduled substances. Nonetheless, recent actions such as a presidential executive order to speed psychedelic access and the FDA's new clinical‑trial guidance are seen as encouraging signs.

Big‑pharma involvement is evident, highlighted by Eli Lilly's $3.8 billion purchase of AtaiBeckley to enter the space. At the same time, Resilient Pharmaceuticals, formerly Lykos Therapeutics, has resubmitted its MDMA therapy application after addressing FDA feedback.

Sam Watson, CEO of BLS Pharmac, described the fast‑track approval push as a positive development for companies seeking U.S. market share.